Playback speed
10 seconds
This video is featured in the 2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Safety & Activity of First-in-Class Dual AR Degrader & Antagonist BMS-986365 in Heavily Pretreated mCRPC Patients
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Andrew Armstrong
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Andrew Armstrong
24 views
October 16, 2024
Comments 0
Login to view comments.
Click here to Login